Merus N.V. a clinical-stage oncology company specializing in the development of innovative multispecific antibodies, has announced significant advancements in its clinical trials for petosemtamab, a novel therapy targeting epidermal growth factor receptor (EGFR) and LGR5. The company has recently initiated two pivotal clinical trials, expanding its exploration of petosemtamab’s efficacy in treating different malignancies, specifically recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) and metastatic colorectal cancer (mCRC).
On September 30, 2024, Merus reported that the first patient has been dosed in the Phase 3 trial known as LiGeR-HN1. This trial is designed to evaluate the safety and efficacy of petosemtamab when used in combination with pembrolizumab, an established checkpoint inhibitor, in patients with PD-L1 positive r/m HNSCC. The LiGeR-HN1 trial aims to compare the combination therapy against pembrolizumab monotherapy as the first-line treatment approach. The inclusion of petosemtamab, classified as a Biclonics dual-targeting antibody, is expected to enhance the therapeutic impact in this patient population.
In addition, on July 8, 2024, Merus announced the successful dosing of the first patient in a Phase 2 clinical trial investigating petosemtamab in combination with standard chemotherapy for patients with second-line mCRC. This follows feedback from the FDA, confirming the use of a 1500 mg dosage of petosemtamab administered every two weeks, which has been retained for both the Phase 3 trials LiGeR-HN1 and LiGeR-HN2 (evaluating subsequent lines of therapy for r/m HNSCC).
These developments underscore Merus’ commitment to advancing treatment options utilizing its unique Biclonics platform in oncology. The ongoing trials, particularly LiGeR-HN1, represent a critical step in examining the potential benefits of dual-targeting treatments in areas with high unmet medical needs.
As Merus progresses through these pivotal studies, the outcomes will be closely monitored by the oncology community and stakeholders. The results could contribute significantly to the evolving landscape of treatment strategies for patients battling head and neck cancers, as well as metastatic colorectal cancer, marking a potential advancement in personalized oncology therapies.
Comments